Showing results (31-40 of 463) with videos related to
Sort By:
Pageof 47
Expert Opinion on Drug Safety|September 2, 2020
Safety considerations when using non-ergot dopamine agonists to treat Parkinson's diseaseFabrizio Stocchi, Barbara Fossati, Margherita TortiTranslational Neurodegeneration|May 15, 2015
How to optimize the treatment of early stage Parkinson's diseaseFabrizio Stocchi, Laura Vacca, Fabiana G RadicatiMovement Disorders : Official Journal of the Movement Disorder Society|September 11, 2008
Treatment of levodopa-induced motor complicationsFabrizio Stocchi, Michele Tagliati, C Warren OlanowExpert Opinion on Drug Safety|February 5, 2014
Drug safety evaluation of ropinirole prolonged releaseFabrizio Stocchi, Fabiana G Radicati, Margherita TortiNeurology|December 10, 2003
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PDPeter JennerNeurology|July 21, 2005
A novel dopamine agonist for the transdermal treatment of Parkinson's diseasePeter JennerNeurology|March 23, 2002
Pharmacology of dopamine agonists in the treatment of Parkinson's diseasePeter JennerAnnals of Neurology|January 8, 2009
Functional models of Parkinson's disease: a valuable tool in the development of novel therapiesPeter JennerCurrent Opinion in Neurology|June 8, 2004
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's diseasePeter JennerInternational Review of Neurobiology|September 2, 2014
An overview of adenosine A2A receptor antagonists in Parkinson's diseasePeter JennerPageof 47